Bioventus Inc. (BVS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 7.45 |
| Open | 7.59 |
| Bid | 5.51 x 200 |
| Ask | 7.50 x 400 |
| Day's range | 7.33 - 7.59 |
| 52-week range | 2.82 - 7.76 |
| Volume | |
| Avg. volume | 516,279 |
| Market cap | 476.792M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.33 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.50 |
ZacksMerck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
ZacksHere's Why You Should Consider Buying Bioventus (BVS) Stock
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
ZacksJ&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
© 2024 Yahoo. All rights reserved.